Humanized anti-alpha v beta 6 mAb ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 85 | 特発性間質性肺炎 | 10 |
85. 特発性間質性肺炎
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003158-18-DE (EUCTR) | 30/04/2019 | 21/06/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - SPIRIT | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 2 | EUCTR2017-003158-18-PL (EUCTR) | 18/02/2019 | 30/11/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 290 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 3 | EUCTR2017-003158-18-DK (EUCTR) | 15/11/2018 | 16/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Australia;Netherlands;Germany;Korea, Republic of | ||
| 4 | EUCTR2017-003158-18-NL (EUCTR) | 10/10/2018 | 24/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - SPIRIT | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 5 | EUCTR2017-003158-18-BE (EUCTR) | 26/09/2018 | 29/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 6 | EUCTR2017-003158-18-GR (EUCTR) | 21/09/2018 | 25/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 7 | EUCTR2017-003158-18-GB (EUCTR) | 18/09/2018 | 10/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - 203PF203 | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 290 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 8 | EUCTR2017-003158-18-CZ (EUCTR) | 12/09/2018 | 09/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 9 | EUCTR2017-003158-18-IT (EUCTR) | 03/09/2018 | 05/11/2020 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: NA Product Name: humanized anti-alpha v beta 6 mAb Product Code: [BG00011] INN or Proposed INN: Not yet assigned | BIOGEN IDEC RESEARCH LIMITED | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Czechia;Greece;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 10 | EUCTR2017-003158-18-ES (EUCTR) | 27/07/2018 | 05/06/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of |